Facebook Instagram Twitter RSS Feed Back to top on side

Odbor medzinárodnej spolupráce informuje

PRE-ANNOUNCEMENT - EJP RD JTC2022

15. 11. 2021 | zhliadnuté 78-krát

Konzorcium European Joint Programme on Rare Diseases (EJP RD), ktorého súčasťou je aj SAV, oznamuje, že v decembri 2021 otvorí výzvu na podávanie medzinárodných interdisciplinárnych projektov na tému

 

"Development of new analytic tools and pathways to accelerate diagnosis and facilitate diagnostic monitoring of rare diseases"

 

TÉMA VÝZVY

Projektové návrhy by mali pokryť aspoň jednu z nasledujúcich tém:

  • Phenotype-driven diagnosis: integration across different ontologies, integration of shared pathways, digital phenotyping, development of artificial intelligence approaches/applications to extract health related data in aid of diagnosis; 
  • Prognostic markers/biomarkers investigations for early diagnosis and monitoring; 
  •  Methodologies for solving cases that are currently difficult to analyze due to different underlying mechanisms (e.g. mosaicism, genomic (non-coding) alterations, gene regulation, complex inheritance), including new genomics / functional genomics technologies, multi-omics, mathematics, biostatistics, bioinformatics and artificial intelligence approaches;  
  •  Functional strategies to globally stratify variants of unknown significance (VUS) for clinical use; setting up of (in vitro) systems to distinguish between VUS and pathogenic variants (e.g. confirming disruption of splicing for deep intronic variants, loss of protein function, and gain of toxic protein function);  
  • Development of pathway models to enable diagnosis, especially for newly discovered diseases that may share underlying molecular mechanisms with already known diseases.  It is possible to use cellular and animal models for validation of the new diagnostic approaches in the subtopics listed above where relevant.

(It is possible to use cellular and animal models for validation of the new diagnostic approaches in the subtopics listed above where relevant.)

Nasledujúce prístupy a témy sú vylúčené zo záberu tejto výzvy:

  • Interventional clinical trials to prove efficacy of drugs, treatments, surgical procedures, medical technology procedures. This also includes studies comparing efficacy, e.g.  two surgical techniques or therapies. Clinical phase IV pharmacovigilance studies cannot be funded either.
  • Studies on the exclusive testing of the safety of medical devices. 
  • Development of new therapies as covered in EJP RD JTC 2020.
  • Projects focusing only on rare neurodegenerative diseases which are within the main focus of the Joint Programming Initiative on Neurodegenerative Disease Research (JPND). These are: Alzheimer’s disease and other dementias; Parkinson’s disease (PD) and PD-related disorders; Prion diseases; Motor Neuron Diseases; Huntington’s disease; Spinal Muscular Atrophy and dominant forms of Spinocerebellar Ataxia. Interested researchers should refer to the relevant JPND calls. However, childhood dementias/neurodegenerative diseases are not excluded.
  • Rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases. Rare diseases with a predisposition to cancer are not excluded.

 

PREDBEŽNÝ ZOZNAM PARTICIPUJÚCICH ORGANIZÁCIÍ

Na výzve sa predbežne podieľajú nasledujúce národné a regionálne financujúce organizácie, ktoré podporia multilaterálne výskumné projekty s účasťou vedcov z príslušných krajín/regiónov.

  • Medical Research Future Fund (MRFF), Australia
  • Austrian Science Fund (FWF), Austria*
  • Research Foundation Flanders (FWO), Belgium, Flanders
  • Fund for Scientific Research - FNRS (F.R.S.-FNRS), Belgium, French-speaking community
  • Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
  • Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
  • Ministry of Education, Youth and Sports (MEYS), Czech Republic 
  • Academy of Finland (AKA), Finland
  • French National Research Agency (ANR), France
  • Foundation For Rare Diseases (FFRD), France
  • German Ministry of Education and Research (BMBF), Germany 
  • National Research, Development and Innovation Office (NKFIH), Hungary* 
  • Health Research Board (HRB), Ireland*
  • Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
  • Italian Ministry of Health (MoH-IT), Italy
  • Regional Foundation for Biomedical Research (FRRB), Lombardy (Italy)
  • Tuscany Region (RT/TuscReg), Tuscany (Italy)
  • Research Council of Lithuania (LMT), Lithuania
  • National Research Fund (FNR), Luxembourg
  • National Centre for Research and Development (NCBR), Poland
  • Slovak Academy of Sciences (SAS), Slovakia
  • National Institute of Health Carlos III (ISCIII), Spain
  • Swedish Research Council (SRC), Sweden
  • Vinnova, Sweden
  • Swiss National Science Foundation (SNSF), Switzerland
  • Netherlands Organization for Health Research and Development (ZonMw)The Netherlands*
  • The Scientific and Technological Research Council of Turkey (TUBITAK), Turkey* 

*Účasť vo výzve ešte nepotvrdená

 

PREDBEŽNÝ HARMONOGRAM

16 december 2021 Informačný webinár pre žiadateľov

16 február 2022

Termín na podanie prvotných projektových návrhov - preproposal (1. kolo)

koniec apríla 2022

Pozvanie do 2. kola hodnotenia

15 jún 2022

Termín na podanie kompletných návrhov projektov - full proposal (2.kolo)

28 júl 2022

Odpoveď na externé posudky - rebuttal

December 2022

Oznámenie výsledkov

 

Predsedníctvo SAV uznesením č. 136 zo dňa 14. 10. 2021 súhlasilo so zapojením SAV do tejto výzvy a s finančnou podporou 1 projektu do maximálnej výšky 40 000€/rok (z čoho 15 000 €/rok je povinná spoluúčasť príslušnej organizácie SAV) naobdobie 3 rokov.

 

Bližšie informácie sú dostupné v prílohe a na stránke konzorcia: https://www.ejprarediseases.org/joint-transnational-call-2022/

Nástroj na vyhľadávanie partnerov: https://live.eventtia.com/en/jtc2022matchmaking

 

Kontaktná osoba: Zuzana Černáková, +421 2 57510118, cernakova@up.upsav.sk -